Norges Bank acquired a new stake in Prothena Co. plc (NASDAQ:PRTA - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 57,454 shares of the biotechnology company's stock, valued at approximately $796,000. Norges Bank owned 0.11% of Prothena at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently modified their holdings of the company. XTX Topco Ltd acquired a new position in shares of Prothena during the third quarter worth approximately $260,000. Orion Portfolio Solutions LLC boosted its position in Prothena by 4.4% in the third quarter. Orion Portfolio Solutions LLC now owns 17,531 shares of the biotechnology company's stock worth $293,000 after purchasing an additional 739 shares during the last quarter. Barclays PLC increased its holdings in Prothena by 110.2% during the third quarter. Barclays PLC now owns 95,222 shares of the biotechnology company's stock worth $1,592,000 after buying an additional 49,916 shares during the last quarter. Hennion & Walsh Asset Management Inc. bought a new stake in shares of Prothena in the 4th quarter worth approximately $724,000. Finally, SG Americas Securities LLC increased its holdings in Prothena by 167.0% in the 4th quarter. SG Americas Securities LLC now owns 37,612 shares of the biotechnology company's stock worth $521,000 after acquiring an additional 23,525 shares during the last quarter. 97.08% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of equities analysts have recently commented on the company. StockNews.com raised Prothena from a "sell" rating to a "hold" rating in a report on Monday, February 24th. Cantor Fitzgerald reissued an "overweight" rating on shares of Prothena in a research note on Friday, February 21st. HC Wainwright reissued a "buy" rating and set a $48.00 target price on shares of Prothena in a research note on Friday, February 21st. Bank of America reduced their price target on shares of Prothena from $26.00 to $22.00 and set a "neutral" rating on the stock in a research report on Thursday, December 19th. Finally, Piper Sandler increased their price target on shares of Prothena from $94.00 to $110.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $55.00.
Read Our Latest Analysis on PRTA
Prothena Stock Performance
Shares of PRTA stock traded down $0.06 during trading hours on Thursday, reaching $9.20. The company had a trading volume of 103,686 shares, compared to its average volume of 442,087. The firm has a market cap of $495.15 million, a PE ratio of -4.00 and a beta of 0.07. Prothena Co. plc has a one year low of $9.10 and a one year high of $25.42. The business has a fifty day moving average price of $13.08 and a 200-day moving average price of $14.54.
Prothena (NASDAQ:PRTA - Get Free Report) last posted its earnings results on Thursday, February 20th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.06). Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. The firm had revenue of $2.12 million during the quarter, compared to the consensus estimate of $7.53 million. Equities research analysts forecast that Prothena Co. plc will post -4.04 EPS for the current year.
About Prothena
(
Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
See Also
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
